Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

TMC 125

Known as: TMC-125, TMC125 cpd 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Etravirine (TMC-125, ETV) is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) that demonstrates potent… Expand
  • figure 1
  • figure 2
  • table 1
2010
2010
Novel 2-aryalkylthio-4-amino-6-benzylpyrimidines (3a-i), which can be considered as S-DABO and TMC-125 analogue hybrid molecules… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
2009
2009
ABSTRACT Susceptibility to etravirine (ETR), an expanded-spectrum nonnucleoside reverse transcriptase inhibitor (NNRTI), is… Expand
2008
2008
It is mandatory to find antiretroviral therapies that offer increased efficacy in treatmentexperienced patients with HIV-1… Expand
  • figure 1
Highly Cited
2007
Highly Cited
2007
HIV reverse transcriptase (HIV-RT) contains two distinct protein domains catalyzing DNA polymerase and RNase H activities. Non… Expand
2007
2007
TMC125 is a next-generation NNRTI with potent activity against both wild-type HIV-1 and HIV-1 resistant to current NNRTIs1 Two… Expand
Review
2007
Review
2007
On 3 previous occasions, in 2002, 2003 and 2005, the Swedish Medical Products Agency (Läkemedelsverket) and the Swedish Reference… Expand
2007
2007
In the category ‘Best new drug’: raltegravir This integrase inhibitor was previously called MK-0518 and will have the trade name… Expand
2005
2005
In order to study the inhibitory effect of various reverse transcriptase inhibitors (RTIs) on cell-free HIV, we adapted a… Expand
Review
2004
Review
2004
TMC-125, a non-nucleoside reverse transcriptase inhibitor, is being developed by Tibotec for the potential treatment of HIV… Expand